DermBiont CEO and leadership

Karl Beutner, MD, PhD, is DermBiont’s CEO and CMO leading drug development efforts. Dr. Beutner will apply his extensive background in dermatology and infectious disease drug development to build DermBiont's clinical development capabilities. Karl brings more than 25 years of experience in medicine most recently from Anacor Pharmaceuticals where he served as Chief Medical Officer in addition to serving as a senior executive with several established healthcare organizations and as a practicing physician.

Nick's investment expertise spans across asset classes with an extensive focus on microbiome oriented companies across all stages of venture capital. Nick is a Managing Partner at Olive Tree Capital; he led his last company through acquisition and has successfully seeded and structured companies across multiple industries. His passion for the Microbiome originates from personal experiences with skin infections and c-diff. Nick graduated with honors from Boston University’s Questrom School of Business and started his career in commodity markets at CPM Group in New York.

Dr. Robert Brucker leads research efforts at DermBiont and received his B.S. in Biology from the University of Mount Union in 2007 and earned a PhD in Biomedical Sciences from Vanderbilt University in 2013. He is currently a Rowland Junior Fellow at Harvard University where he runs a research program on applied microbiomes. Robert has 19 publications related to host-microbe associations (published in journals Nature ISME, Science, and Nature Communications), including experimental probiotic trials for antifungal activity. He has over a decade of genetics, microbiology, and applied microbiota experience.

Daniel Geffken has served as a member of the Windtree Board of Directors since April 2019. He serves as Chairman of the Board’s Audit Committee and is a member of the Compensation Committee. Mr. Geffken has more than 30 years of financial management experience to the board, ranging from start-ups to publicly traded companies with over $1 billion market capitalizations. Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has also served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Directors of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra. Since 2013, he has assisted in ten initial public offering filings. Over the course of his career, he has assisted in raising more than $1 billion in equity and debt securities for life science companies.

Daniel holds a BS from The Wharton School, University of Pennsylvania, and an MBA from Harvard Business School.

Karl Beutner, MD, PhD, is DermBiont’s CEO and CMO leading drug development efforts. Dr. Beutner will apply his extensive background in dermatology and infectious disease drug development to build DermBiont's clinical development capabilities. Karl brings more than 25 years of experience in medicine most recently from Anacor Pharmaceuticals where he served as Chief Medical Officer in addition to serving as a senior executive with several established healthcare organizations and as a practicing physician.

Nick's investment expertise spans across asset classes with an extensive focus on microbiome oriented companies across all stages of venture capital. Nick is a Managing Partner at Olive Tree Capital; he led his last company through acquisition and has successfully seeded and structured companies across multiple industries. His passion for the Microbiome originates from personal experiences with skin infections and c-diff. Nick graduated with honors from Boston University’s Questrom School of Business and started his career in commodity markets at CPM Group in New York.

Dr. Robert Brucker leads research efforts at DermBiont and received his B.S. in Biology from the University of Mount Union in 2007 and earned a PhD in Biomedical Sciences from Vanderbilt University in 2013. He is currently a Rowland Junior Fellow at Harvard University where he runs a research program on applied microbiomes. Robert has 19 publications related to host-microbe associations (published in journals Nature ISME, Science, and Nature Communications), including experimental probiotic trials for antifungal activity. He has over a decade of genetics, microbiology, and applied microbiota experience.